Journal Impact Factor 1.0* ; 1.93* (5 Year Impact Factor)
International Journal of Clinical Rheumatology is at the cutting edge of the most recent clinical, translational and lab based exploration to propel the treatment for a wide range of rheumatic diseases and disorders which includes themes, for example, treatment, surgery, imaging and clinical education.
The journal is committed to distribute most elevated quality studies identified with clinical determination and administration of rheumatic ailments through facilitated parts of clinical consideration and clinical examination concentrated on propelling treatment and personal satisfaction for individuals with joint pain, immune system infections, bone issue and related conditions. This journal offers an open access platform to Rheumatology community where, the authors can publish all the reliable sources of information on research findings and current developments as original articles, reviews, case studies, clinical images, short communications, commentaries, etc. and all the published materials will be accessed online all over the world without any subscription fee. The journal gives fundamental perusing to rheumatologists and additionally orthopedic specialists, pharmacologists, pathologists, radiologists, general experts and other wellbeing experts with an enthusiasm for patients with rheumatic maladies.
The journal also incorporates original papers inside the assorted fields of rheumatology, clinical experimentation as well as medicine, pathologic process, immunology, immunopathology, microbiology and different types of radiological studies.
Indexing: Scopus, Scimago, Excerpta Medica (EMBASE), CAS (Chemical Abstracts Service)
Submit your manuscripts through Editorial Manager: http://www.editorialmanager.com/openaccessjournals
Author(s): Ivan Rihacek, Petr Nemec, Michal Rihacek, Bohuslav Kianicka, Andrius Berukstis, Martin Caprnda, Ludovit Gaspar, Peter Kruzliak*, Miroslav Soucek
Background: To assess hypertension related cardiovascular risk parameters in patients with rheumatoid arthritis. To determine the effect of long-term treatment with corticosteroids, non-ster..
Author(s): Tamer A. Gheita and Hanan M Fathi
Author(s): Sultan M. Al Mogairen
Background: Adalimumab is a known drug modifying agent for rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA) treatment. However little is known about the risk of nephrotoxici..
Author(s): Maria Khalid, Shafia Tufail, Zunaira Aslam, Ayesha Butt*
Background: Osteoarthritis (OA) is a degenerative disorder that affects the cartilage of bones and characterized by severe pain in joint, joint lock and instability. Factors associated with ..